Corrigendum to “The Current Practice of Screening, Prevention, and Treatment of Androgen-Deprivation-Therapy Induced Osteoporosis in Patients with Prostate Cancer”

Al-Shamsi HO, Lau AN, Malik K, Alamri A, Ioannidis G, Corbett T, Adachi JD, Papaioannou A.
J Oncol. 2017;2017:3432604. doi: 10.1155/2017/3432604. Epub 2017 Dec 3.

In the article titled “The Current Practice of Screening, Prevention, and Treatment of Androgen-Deprivation-therapy Induced Osteoporosis in Patients with Prostate Cancer”, there was an error regarding the FRAX® tool, which should be clarified as follows.

The article notes: “As a result of the potential consequences of ADT, expert guideline recommendations advocate for assessing men prescribed ADT for osteoporosis and to estimate the baseline fracture risk using an assessment tool, such as the World Health Organization fracture risk assessment tool [6, 21, 32, 33]”. However, the World Health Organization(WHO) did not develop, test, or endorse the FRAX® tool or its recommendations. The metabolic bone disease unit at the University of Sheffield that developed FRAX® was a WHO Collaborating Centre from 1991 to 2010, but treatment guidelines must undergo a formal process before they can been endorsed by the WHO.

0 Comments
Submit a Comment

Your email address will not be published. Required fields are marked *

Share This
×